Related Experiment Video
Updated: Mar 19, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Hyperphosphatemia Management in Patients with Chronic Kidney Disease
Ahmed M Shaman1, Stefan R Kowalski2
1Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Insights
Managing hyperphosphatemia in chronic kidney disease (CKD) is crucial to prevent complications like cardiovascular calcification. This review explores phosphorus homeostasis and CKD management strategies, including factors affecting phosphate binder efficacy.
Area of Science:
- Nephrology
- Endocrinology
- Cardiovascular Medicine
Background:
- Hyperphosphatemia in chronic kidney disease (CKD) is linked to severe complications, including cardiovascular calcification, renal osteodystrophy, and secondary hyperparathyroidism (SHPT).
- Elevated phosphate levels in CKD patients correlate with increased cardiovascular disease incidence and mortality.
- Understanding phosphorus homeostasis is essential for effective hyperphosphatemia management in CKD.
Purpose of the Study:
- To provide a comprehensive review of phosphorus homeostasis.
- To discuss current management strategies for hyperphosphatemia in CKD patients.
- To highlight reasons for treatment failure, focusing on gastric pH impact on phosphate binders.
Main Methods:
- Literature review of studies on phosphorus homeostasis.
- Analysis of pharmacological and non-pharmacological treatment options for hyperphosphatemia.
- Examination of factors influencing phosphate binder efficacy, particularly gastric pH.
Main Results:
- Review details the complex physiologic pathways of phosphorus balance.
- Identifies key treatment approaches for managing elevated phosphate levels in CKD.
- Emphasizes the significant role of gastric pH in determining the effectiveness of oral phosphate binders.
Conclusions:
- Effective hyperphosphatemia management in CKD requires a thorough understanding of phosphorus balance and treatment options.
- Gastric pH significantly impacts phosphate binder efficiency, representing a critical factor in treatment success.
- Addressing factors like gastric pH is vital for optimizing hyperphosphatemia control in CKD patients.
Abstract:
Hyperphosphatemia in chronic kidney disease (CKD) patients is a potentially life altering condition that can lead to cardiovascular calcification, metabolic bone disease (renal osteodystrophy) and the development of secondary hyperparathyroidism (SHPT). It is also associated with increased prevalence of cardiovascular diseases and mortality rates. To effectively manage hyperphosphatemia in CKD patients it is important to not only consider pharmacological and nonpharmacological treatment options but also to understand the underlying physiologic pathways involved in phosphorus homoeostasis. This review will therefore provide both a background into phosphorus homoeostasis and the management of hyperphosphatemia in CKD patients. In addition, it will cover some of the most important reasons for failure to control hyperphosphatemia with emphasis on the effect of the gastric pH on phosphate binders efficiency.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Peritoneal Dialysis III: Nursing Management
Acute Kidney Injury VI: Nursing Management

